John Renger - Feb 6, 2024 Form 4 Insider Report for Cerevel Therapeutics Holdings, Inc. (CERE)

Role
Chief Scientific Officer
Signature
/s/ Mark Bodenrader, as Attorney-in-Fact
Stock symbol
CERE
Transactions as of
Feb 6, 2024
Transactions value $
-$89,777
Form type
4
Date filed
2/8/2024, 07:19 PM
Previous filing
Jan 23, 2024
Next filing
Aug 5, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CERE Common Stock Options Exercise +5.02K +142.98% 8.53K Feb 6, 2024 Direct F1, F2
transaction CERE Common Stock Sale -$89.8K -2.16K -25.33% $41.54 6.37K Feb 7, 2024 Direct F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CERE Restricted Stock Units Options Exercise $0 -5.02K -25% $0.00 15.1K Feb 6, 2024 Common Stock 5.02K Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents the contingent right to receive one share of the Issuer's common stock.
F2 Includes 807 shares previously acquired under the Issuer's Employee Stock Purchase Plan on June 30, 2023.
F3 The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $41.42 to $41.70. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5 The RSUs vest in four equal annual installments on each of February 6, 2024, February 6, 2025, February 6, 2026 and February 6, 2027, subject to the Reporting Person's continued service on each such vesting date.